Depression Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019-2026

The report analyzes and forecasts the depression drugs market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.

This report first introduces the background of depression drugs, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major depression drugs companies.

Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of depression drugs upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of depression drugs and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.

The report comprises a detailed value chain analysis, which provides a comprehensive view of the global depression drugs market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.

The study provides a decisive view of the depression drugs market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

The report provides size (in terms of volume and value) of depression drugs market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.

The report also profiles major players operating in the global depression drugs market based on various attributes, such as, company overview, financial overview, product portfolio, business strategies, SWOT analysis, and recent developments. Major players profiled in this report include Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Pfizer Inc., AstraZeneca, Allergan USA, Inc., Novartis AG, GlaxoSmithKline, and Takeda Pharmaceutical Company Ltd.

The global depression drugs market has been segmented as below:

Global Depression Drugs Market, by Drug Class

  • Atypical antipsychotics
  • Serotonin-norepinephrine reuptake inhibitors
  • Selective serotonin reuptake inhibitors
  • CNS stimulants
  • Others (Benzodiazepines and miscellaneous antidepressants)

Global Depression Drugs Market, by Disease Type

  • Major depressive disorders
  • Schizophrenia and bipolar I disorder (manic depression)
  • SSRI induced
  • Others (attention deficit hyperactivity disorder and anxiety disorders)

Global Depression Drugs Market, by Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

Global Depression Drugs Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • U.K.
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Rest of Middle East & Africa

Research Methodology:

In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.

Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.

Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.

The study objectives of this report are:

  • To analyze and study the global depression drugs capacity, production, value, consumption, status (2014-2018) and forecast (2019-2026);
  • Market value USD Million and volume Units Million data for each segment and sub-segment
  • Focuses on the key depression drugs manufacturers, to study the capacity, production, value, market share and development plans in future.
  • Focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.
  • To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
  • To identify significant trends and factors driving or inhibiting the market growth.
  • To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
  • To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
  • To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
  • To strategically profile the key players and comprehensively analyze their growth strategies.

1. Preface
     1.1. Market Segmentation
     1.2. Key Research Objectives
     1.3. Research Highlights

2.  Assumptions and Acronyms Used

3. Research Approach & Methodology
     3.1. Research Methodology overview
     3.2. Project Initiation
     3.3. Secondary Research Methodology
     3.4. Primary Research Methodology
     3.5. Analysis Research Methodology
     3.6. Final Report & Conclusions Research Methodology

4. Executive Summary: Global Depression Drugs Market

5.  Market Overview
     5.1. Overview
     5.2. Key Industry Events and Developments
     5.3. Global Depression Drugs Market Forecast and Analysis
     5.4. Global Depression Drugs Market Outlook

6. Market Dynamics
     6.1. Drivers and Restraints Snapshot Analysis
     6.2. Drivers
     6.3. Restraints
     6.4. Opportunities
     6.5. Key Trends
     6.6. Pipeline Analysis
     6.7. Depression Treatment Market Value Chain Analysis

7. Global Depression Drugs Market, by Drug Class
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Global Depression Drugs Market, by Drug Class
            7.3.1. Atypical antipsychotics
            7.3.2. Serotonin-norepinephrine reuptake inhibitors
            7.3.3. Selective serotonin reuptake inhibitors
            7.3.4. CNS stimulants
            7.3.4. Others (Benzodiazepines and miscellaneous antidepressants)
     7.4. Global Depression Drugs Market Share Analysis, by Drug Class
     7.5. Global Depression Drugs Market Forecast, by Drug Class
     7.6. Global Depression Drugs Market Analysis, by Drug Class

8. Global Depression Drugs Market, by Disease Type
     8.1. Introduction & Definition
     8.2. Key Findings / Developments
     8.3. Global Depression Drugs Market, by Disease Type
            8.3.1. Major Depressive Disorder
            8.3.2. Schizophrenia and bipolar I disorder (manic depression)
            8.3.3. SSRI induced
            8.3.4. Others (attention deficit hyperactivity disorder and anxiety disorders)
     8.4. Global Depression Drugs Market Value Share Analysis, by Disease Type
     8.5. Global Depression Drugs Market Forecast, by Disease Type
     8.6. Global Depression Drugs Market Analysis, by Disease Type

9. Global Depression Drugs Market, by Distribution Channel
     9.1. Introduction & Definition
     9.2. Key Findings / Developments
     9.3. Global Depression Drugs Market, by Distribution Channel
            9.3.1. Hospital pharmacies
            9.3.2. Retail pharmacies
            9.3.3. Online pharmacies
     9.4. Global Depression Drugs Market Share Analysis, by Distribution Channel
     9.5. Global Depression Drugs Market Forecast, by Distribution Channel
     9.6. Global Depression Drugs Market Analysis, by Distribution Channel

10. Global Depression Drugs Market, by Region
     10.1. Global Depression Drugs Market Snapshot, by Country/Sub-region
     10.2. Global Depression Drugs Market Analysis, by Region
            10.2.1. North America
            10.2.2. Europe
            10.2.3. Asia Pacific
            10.2.4. Latin America
            10.2.5. Middle East & Africa
     10.3. Global Depression Drugs Market Forecast, by Region

11. North America Depression Drugs Market Analysis
     11.1. Policies and Regulations: U.S.
     11.2. Key Findings
     11.3. North America Depression Drugs Market Overview
     11.4. North America Depression Drugs Market Value Share Analysis, by Drug Class
     11.5. North America Depression Drugs Market Forecast, by Drug Class
            11.5.1. Atypical antipsychotics
            11.5.2. Serotonin-norepinephrine reuptake inhibitors
            11.5.3. Selective serotonin reuptake inhibitors
            11.5.4. CNS stimulants
            11.5.5. Others (Benzodiazepines and miscellaneous antidepressants)
     11.6. North America Depression Drugs Market Value Share Analysis, by Disease Type
     11.7. North America Depression Drugs Market Forecast, by Disease Type
            11.7.1. Major depressive disorder
            11.7.2. Schizophrenia and bipolar I disorder (manic depression)
            11.7.3. Selective serotonin reuptake inhibitors induced
            11.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders)
     11.8. North America Depression Drugs Market Value Share Analysis, by Distribution Channel
     11.9. North America Depression Drugs Market Forecast, by Distribution Channel
            11.9.1. Hospital pharmacies
            11.9.2. Retail pharmacies
            11.9.3. Online pharmacies
     11.10. North America Depression Drugs Market Value Share Analysis, by Country
     11.11. North America Depression Drugs Market Forecast, by Country
            11.11.1. U.S.
            11.11.2. Canada
     11.12. Market Trends North America

12. Europe Depression Drugs Market Analysis
     12.1. Policies and Regulations: Europe
     12.2. Key Findings
     12.3. Europe Depression Drugs Market Overview
     12.4. Europe Depression Drugs Market Value Share Analysis, by Drug Class
     12.5. Europe Depression Drugs Market Forecast, by Drug Class
            12.5.1. Atypical antipsychotics
            12.5.2. Serotonin-norepinephrine reuptake inhibitors
            12.5.3. Selective serotonin reuptake inhibitors
            12.5.4. CNS stimulants
            12.5.5. Others (Benzodiazepines and miscellaneous antidepressants)
     12.6. Europe Depression Drugs Market Value Share Analysis, by Disease Type
     12.7. Europe Depression Drugs Market Forecast, by Disease Type
            12.7.1. Major depressive disorder
            12.7.2. Schizophrenia and bipolar I disorder (manic depression)
            12.7.3. Selective serotonin reuptake inhibitors induced
            12.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders)
     12.8. Europe Depression Drugs Market Value Share Analysis, by Distribution Channel
     12.9. Europe Depression Drugs Market Forecast, by Distribution Channel
            12.9.1. Hospital pharmacies
            12.9.2. Retail pharmacies
            12.9.3. Online pharmacies
     12.10. Europe Depression Drugs Market Value Share Analysis, by Country
     12.11. Europe Depression Drugs Market Forecast, by Country
            12.11.1. Germany
            12.11.2. France
            12.11.3. Italy
            12.11.4. Spain
            12.11.5. U.K.
            12.11.6. Rest of Europe
     12.12. Market Trends Europe

13. Asia Pacific Depression Drugs Market Analysis
     13.1. Policies and Regulations: Asia Pacific
     13.2. Key Findings
     13.3. Asia Pacific Depression Drugs Market Overview
     13.4. Asia Pacific Depression Drugs Market Value Share Analysis, by Drug Class
     13.5. Asia Pacific Depression Drugs Market Forecast, by Drug Class
            13.5.1. Atypical antipsychotics
            13.5.2. Serotonin-norepinephrine reuptake inhibitors
            13.5.3. Selective serotonin reuptake inhibitors
            13.5.4. CNS stimulants
            13.5.5. Others (Benzodiazepines and miscellaneous antidepressants)
     13.6. Asia Pacific depression drugs Market Value Share Analysis, by Disease Type
     13.7. Asia Pacific Depression Drugs Market Forecast, by Disease Type
            13.7.1. Major depressive disorder
            13.7.2. Schizophrenia and bipolar I disorder (manic depression)
            13.7.3. Selective serotonin reuptake inhibitors induced
            13.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders)
     13.8. Asia Pacific Depression Drugs Market Value Share Analysis, by Distribution Channel
     13.9. Asia Pacific Depression Drugs Market Forecast, by Distribution Channel
            13.9.1. Hospital pharmacies
            13.9.2. Retail pharmacies
            13.9.3. Online pharmacies
     13.10. Asia Pacific Depression Drugs Market Value Share Analysis, by Country
     13.11. Asia Pacific Depression Drugs Market Forecast, by Country
            13.11.1. China
            13.11.2. Japan
            13.11.3. India
            13.11.4. Australia & New Zealand
            13.11.5. Rest of Asia Pacific
     13.12. Market Trends Asia Pacific

14. Latin America Depression Drugs Market Analysis
     14.1. Policies and Regulations: Latin America
     14.2. Key Findings
     14.3. Latin America Depression Drugs Market Overview
     14.4. Latin America Depression Drugs Market Value Share Analysis, by Drug Class
     14.5. Latin America Depression Drugs Market Forecast, by Drug Class
            14.5.1. Atypical antipsychotics
            14.5.2. Serotonin-norepinephrine reuptake inhibitors
            14.5.3. Selective serotonin reuptake inhibitors
            14.5.4. CNS stimulants
            14.5.5. Others (Benzodiazepines and miscellaneous antidepressants)
     14.6. Latin America depression drugs Market Value Share Analysis, by Disease Type
     14.7. Latin America Depression Drugs Market Forecast, by Disease Type
            14.7.1. Major depressive disorder
            14.7.2. Schizophrenia and bipolar I disorder (manic depression)
            14.7.3. Selective serotonin reuptake inhibitors induced
            14.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders)
     14.8. Latin America Depression Drugs Market Value Share Analysis, by Distribution Channel
     14.9. Latin America Depression Drugs Market Forecast, by Distribution Channel
            14.9.1. Hospital pharmacies
            14.9.2. Retail pharmacies
            14.9.3. Online pharmacies
     14.10. Latin America Depression Drugs Market Value Share Analysis, by Country
     14.11. Latin America Depression Drugs Market Forecast, by Country
            14.11.1. Brazil
            14.11.2. Mexico
            14.11.3. Rest of Latin America
     14.12. Market Trends Latin America

15. Middle East & Africa Depression Drugs Market Analysis
     15.1. Policies and Regulations: Middle East & Africa
     15.2. Key Findings
     15.3. Middle East & Africa Depression Drugs Market Overview
     15.4. Middle East & Africa Depression Drugs Market Value Share Analysis, by Drug Class
     15.5. Middle East & Africa Depression Drugs Market Forecast, by Drug class
            15.5.1. Atypical antipsychotics
            15.5.2. Serotonin-norepinephrine reuptake inhibitors
            15.5.3. Selective serotonin reuptake inhibitors
            15.5.4. CNS stimulants
            15.5.5. Others (Benzodiazepines and miscellaneous antidepressants)
     15.6. Middle East & Africa Depression Drugs Market Value Share Analysis, by Disease Type
     15.7. Middle East & Africa Depression Drugs Market Forecast, by Disease Type
            15.7.1. Major depressive disorder
            15.7.2. Schizophrenia and bipolar I disorder (manic depression)
            15.7.3. Selective serotonin reuptake inhibitors induced
            15.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders)
     15.8. Middle East & Africa Depression Drugs Market Value Share Analysis, by Distribution Channel
     15.9. Middle East & Africa Depression Drugs Market Forecast, by Distribution Channel
            15.9.1. Hospital pharmacies
            15.9.2. Retail pharmacies
            15.9.3. Online pharmacies
     15.10. Middle East & Africa Depression Drugs Market Value Share Analysis, by Country
     15.11. Middle East & Africa Depression Drugs Market Forecast, by Country
            15.11.1. GCC
            15.11.2. South Africa
            15.11.3. Israel
            15.11.4. Rest of Middle East & Africa
     15.12. Market Trends Middle East & Africa

16. Competition Landscape
     16.1. Competition Matrix
     16.2. Depression Drugs Market Share Analysis, by Company
     16.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            16.3.1. Otsuka Pharmaceutical Co., Ltd.
                     16.3.1.1. Company Description
                     16.3.1.2. Financial Overview
                     16.3.1.3. Recent Developments
                     16.3.1.4. Strategic Overview
                     16.3.1.4. SWOT Analysis
            16.3.2. Eli Lilly and Company
                     16.3.2.1. Company Description
                     16.3.2.2. Financial Overview
                     16.3.2.3. Strategic Overview
                     16.3.2.4. SWOT Analysis
            16.3.3. Pfizer, Inc.
                     16.3.3.1. Company Description
                     16.3.3.2. Financial Overview
                     16.3.3.3. Strategic Overview
                     16.3.3.4. SWOT Analysis
            16.3.4. AstraZeneca plc.
                     16.3.4.1. Company Description
                     16.3.4.2. Financial Overview
                     16.3.4.3. SWOT Analysis
            16.3.5. Novartis AG
                     16.3.5.1. Company Description
                     16.3.5.2. Financial Overview
                     16.3.5.3. Strategic Overview
                     16.3.5.4. SWOT Analysis
            16.3.6. GlaxoSmithKline plc
                     16.3.6.1. Company Description
                     16.3.6.2. Financial Overview
                     16.3.6.3. Strategic Overview
                     16.3.6.4. Recent Developments
                     16.3.6.5. SWOT Analysis
            16.3.7. Takeda Pharmaceutical Company Ltd
                     16.3.7.1. Company Description
                     16.3.7.2. Financial Overview
                     16.3.7.3. Strategic Overview
                     16.3.7.4. SWOT Analysis
            16.3.8. Sebela Pharmaceutical Inc.
                     16.3.8.1. Company Description
                     16.3.8.2. Financial Overview
                     16.3.8.3. Strategic Overview
                     16.3.8.3. SWOT Analysis
            16.3.9. Allergan USA, Inc.
                     16.3.9.1. Company Description
                     16.3.9.2. Financial Overview
                     16.3.9.3. Strategic Overview
                     16.3.9.3. SWOT Analysis
            16.3.10. Johnson & Johnson
                     16.3.10.1. Company Description
                     16.3.10.2. Financial Overview
                     16.3.10.3. Strategic Overview
                     16.3.10.4. SWOT Analysis

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers
Ask to Expert